OBJECTIVES: Cancer patients undergo a wide range of laboratory procedures, from simple b...sor要有血液检测，以支持靶向治疗的使用。在制药...

Bu...245 progression free patient years and 408 life years in population covered by private...0.12% - 1.21%). The main cost offsets include the displacement of more widely-used...m...o...PCN52

PCN52

POSITRON EMISSION TOMOGRAHY/COMPUTED TOMOGRAPHY IMAGING FOR NON-SMALL CELL LUNG CANCER: A BUDGET IMPACT ANALYSIS

Wohnschin RE,1 Freitas MC, Silver FG2

1Brazilian Ministry of Health, Brasilia, Brazil, 2Brazilian Ministry of Health, Brasilia, Brazil,

OBJECTIVES: To estimate the budgetary impact of the introduction of PET-CT for staging...4 patients over 21 years from the database (N...e...Patio...The resulting estimate was used as an input of the 21-gene assay in private hospitals would provide good value for money from the national insurance perspectives. The introduction of PET-CT in the staging of NSCLC affects the budget of the Ministry of Health in 21.8%, 19.6% and 17.5% in the years 2013, 2014 and 2015, respectively.

PCN53

BUDGET IMPACT AND INCREMENTAL SURVIVAL BENEFIT OF Eribulin MESYLATE AS A TREATMENT FOR METASTATIC BREAST CANCER IN BRAZIL

Magalhães J,1 Premo M,2 Ilgen A, Jones T,3 Pomerantz D,3 Clark OAC4

1Universidade Federal de Manaus, Manaus, Brazil

OBJECTIVES: To estimate the incremental benefit of eribulin Mesylate (ERBL) as a treatment for metastatic breast cancer (MBC) in patients with 2-5 prior chemotherapy regimens includ...an Cancer registry report and National database (FOSP and INC) treated patients. The treatment of Physician’s Choice (TPC) arm included capetabine, gemcitabine, vinorelbine, docetaxel and paclitaxel...n...Rational for chemotherapy and resource utilization for AE treatment and disease management pre and post progressions was performed. Local Brazil tariffs for each costs unit were applied to an Excel-based model to compare total costs and survival rates with and without eribulin for MBC patients across a 5-year horizon from private payers perspective (assumed to cover 25% of Brazil population).

RESULTS: Applying an MBC prevalence rate, proportion of patients with active disease and treated with...un...The cost of adjuvant chemotherapy in...18,218 per patient from the national insurance perspective (10,305 from the societal perspective). The 21-gene assay was found cost-effective compared to standard practice and cost-saving with inclusion of productivity costs. The absence of an insurance coverage involves a deficit for private hospitals of €13,200 per patient tested.

CONCLUSIONS: Providing the 21-gene assay in French private hospitals would be cost-effective in the French collective perspective. In the absence of reimbursement from primary payers, some private hospitals may cover the cost of companion diagnostics to improve their attractiveness, but the test will be underused, thus depriving patients from a technology that could improve their quality of life and using resources that could be freed up for other patients.

PCN58

COST-EFFECTIVENESS AND BUDGET-IMPACT ANALYSIS OF BRAF INHIBITORS IN PATIENTS WITH METASTATIC MALIGNANT MELANOMA (MM) IN SLOVENIA

GlasnSmihobil A.,1, Halsek-Sturm T,2 Pajnik L,3,4 GlassnSmihobil A.,1,2,3,4 Gl...